ProShare Advisors
IPSC icon

ProShare Advisors’s Century Therapeutics IPSC Stock Holding History

ProShare Advisors’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.5K Buy
+16,137
New +$36.9K ﹤0.01% 1862
2025
Q2 		– Sell
-10,131
Closed -$4.82K – 2129
2025
Q1 		$4.82K Sell
10,131
-3,049
-23% -$2.29K ﹤0.01% 2075
2024
Q4 		$13.3K Buy
+13,180
New +$17.9K ﹤0.01% 2262
2022
Q1 		– Sell
-10,273
Closed -$163K – 2251
2021
Q4 		$163K Buy
+10,273
New +$193K ﹤0.01% 2098

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

ProShare Advisors's IPSC Position: Q2 2026 in Review

ProShare Advisors opened a new position in Century Therapeutics (IPSC) in Q2 2026: 16,137 shares worth $39.5K. The stake represents ﹤0.01% of the portfolio and ranks #1862 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in IPSC as recently as Q1 2025.

ProShare Advisors first reported a position in IPSC in Q4 2021 and has held it in 4 quarters since. The position peaked at $163K in Q4 2021. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • ProShare Advisors held 16,137 shares of Century Therapeutics worth $39.5K as of Q2 2026.
  • Century Therapeutics was a new ProShare Advisors position in Q2 2026.
  • Century Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1862 holding.
  • ProShare Advisors first reported a position in Century Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • ProShare Advisors's Century Therapeutics position peaked at $163K in Q4 2021.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.